Various chemopreventive agents, including mesalazine, anti-TNF agents, and statins have shown promise in reducing the risk of CRC in these patients; however, the evidence is still evolving and further research is required to determine optimal dosing regimens, the long-term effects of chemopreventive agents, and the role of biologics. The gene discussed is TNF; the disease is colorectal carcinoma.